Nutrition in People With a Lower Limb Amputation
Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Feb 16, 2023
Trial Information
Current as of May 02, 2025
Completed
Keywords
ClinConnect Summary
People requiring an LLA are at high risk for adverse clinical outcomes. Undernutrition and low physical activity level may affect clinical outcomes negatively. However, little is known about the nutritional intake, nutritional status and physical activity level in the LLA population, and their association with clinical outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Undergoing or recently (i.e., within the last seven weeks) having undergone a major dysvascular lower limb amputation (i.e., Syme amputation or more proximal level)
- • 18 years or older
- • Able to collaborate
- Exclusion Criteria:
- • Requiring re-amputation
- • Severe malabsorption disease
About University Medical Center Groningen
University Medical Center Groningen (UMCG) is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and extensive education in the medical field. As a prominent sponsor of clinical trials, UMCG leverages its multidisciplinary expertise and state-of-the-art facilities to advance medical knowledge and improve therapeutic outcomes. The center fosters collaboration among researchers, healthcare professionals, and industry partners, aiming to translate scientific discoveries into effective treatments that enhance patient health and well-being. With a focus on ethical standards and regulatory compliance, UMCG is dedicated to conducting clinical trials that contribute to the advancement of medicine and the betterment of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Groningen, , Netherlands
Leeuwarden, , Netherlands
Groningen, , Netherlands
Leeuwarden, Friesland, Netherlands
Emmen, Drenthe, Netherlands
Scheemda, Groningen, Netherlands
Zwolle, Overijssel, Netherlands
Patients applied
Trial Officials
Jan HB Geertzen
Principal Investigator
University Medical Center Groningen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials